IMARC Group, a leading market research company, has recently released a report titled "Radiopharmaceuticals Market Report by Product Type (Diagnostic Nuclear Medicine, Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), End Use (Hospitals and Clinics, Research Institutes, Diagnostic Centers), and Region 2025-2033." The study provides a detailed analysis of the industry, including the global radiopharmaceuticals market trends, share, size, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Radiopharmaceuticals Market Highlights:
- Radiopharmaceuticals Market Size: Valued at USD 5.8 Billion in 2024.
- Radiopharmaceuticals Market Forecast: The market is expected to reach USD 8.9 billion by 2033, exhibiting a growth rate of 4.9% during 2025-2033.
- Market Growth: The radiopharmaceuticals market is projected to grow significantly due to increasing cancer prevalence and advancements in nuclear medicine.
- Key Applications: Major applications include oncology, cardiology, and neurology, with oncology leading the demand.
- Technological Advancements: Innovations in imaging technologies and therapeutic procedures are driving market expansion.
- Regulatory Support: Favorable government regulations and funding for research in nuclear medicine enhance market prospects.
- Regional Insights: North America holds a substantial market share, followed by Europe and the Asia Pacific, due to advanced healthcare infrastructure.
- Major Players: Key companies include Siemens Healthineers, GE Healthcare, and Bracco Imaging, focusing on product development and strategic partnerships.
- Challenges: High costs of radiopharmaceuticals and stringent regulatory requirements pose challenges to market growth.
- Future Trends: Increasing demand for personalized medicine and targeted therapies is expected to shape the future of the market.
Claim Your Free “Radiopharmaceuticals Market” Insights Sample PDF: https://www.imarcgroup.com/radiopharmaceuticals-market/requestsample
Our report includes:
- Market Dynamics
- Market Trends and Market Outlook
- Competitive Analysis
- Industry Segmentation
- Strategic Recommendations
Industry Trends and Drivers:
- The Paradigm Shift to Theranostics (Diagnosis and Therapy):
The main commercial driver for the industry is Theranostics, a combination of a diagnostic radio-pharmaceutical (e.g. Ga-68) and a therapeutic radio-pharmaceutical (e.g. Lu-177 or Ac-225) coupled to the same molecule through a linker. This principle allows the physician to "see" the tumor using extremely accurate PET imaging, followed by "treatment" using radiation that is directed specifically at the tumor and attempting to minimize damage to surrounding normal tissue. The clinical success of radionuclide therapy for hard to treat cancers, such as for prostate cancer ($\text{Lu}-177$ PSMA) and NETs, has incentivized pharmaceutical companies to develop and manufacturer a next generation of alpha and beta emitting radionuclides that will require a large scale-up of manufacture and quality assurance processes. Unlike the first generation of targeted radionuclide imaging agents, the next generation will consist of complex radiopharmaceuticals with an active therapeutic isotope.
- Surging Global Demand Driven by Oncological Imaging and Aging Populations:
More than 80% of all radiopharmaceuticals are used in oncological indications. The most common radiopharmaceutical in PET imaging for the diagnosis, staging and monitoring of treatment response in cancer patients is the $\text{F}-18$ $\text{FDG}$. There are two demographic trends that are driving exponential growth in the market for diagnostic scans. First, as the world's population ages, the incidence of disease associated with aging, including most types of cancer, has increased, leading to a demand for new diagnostic imaging techniques. Secondly, the drive to introduce cancer screening programs worldwide and improve existing ones so as to reduce cancer-related mortality has resulted in an increasing number of patients requiring nuclear medicine examinations for diagnosis and follow-up. The demand from the cancer program is constant and intense throughout the various stages of the supply chain, establishing a huge baseline demand for cyclotron produced short-lived isotopes.
- Overcoming Supply Chain Vulnerabilities and Decentralized Production:
Concerns about the fragility of the radiopharmaceutical supply chain that historically relied on a small number of aging nuclear reactors for bulk production of parent isotopes such as $\text{Molybdenum}-99$ ($\text{Mo}-99$) have also triggered substantial investment in decentralized and alternate production methods (in the case of $\text{Mo}-99$, decaying to the most widely used diagnostic isotope in the world, $\text{Technetium}-99m$ ($\text{Tc}-99m$)). To lower the risk of worldwide shortages, there has been a trend to develop reactor-independent production of key isotopes, including accelerator and cyclotron driven methods for direct and indirect production, Gallium-68 ($\text{Ga}-68$) generators and local high-volume medical cyclotrons to generate $\text{F}-18$ to allow decentralized production of medical isotopes on a just-in-time basis. This is necessary since the short half-lives of most radioisotopes mean that they have to be used as soon as they are made, creating a large market for localized and reliable manufacturers.
Radiopharmaceuticals Market Report Segmentation:
Breakup by Product Type:
- Diagnostic Nuclear Medicine
- Therapeutic Nuclear Medicine
Breakup by Application:
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Others
Breakup by End Use:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centers
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Advanced Accelerator Applications (Novartis AG)
- Bayer AG
- Bracco S.p.A.
- Cardinal Health Inc.
- Curium Pharma
- General Electric Company
- IBA RadioPharma Solutions
- Jubilant Pharma Limited
- Lantheus Medical Imaging Inc
- Nordion Inc. (Sotera Health)
- NTP Radioisotopes SOC Ltd
- PharmaLogic Holdings Corp
- Siemens AG
Ask Analyst For Request Customization: https://www.imarcgroup.com/request?type=report&id=3906&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1–201971–6302
